Lenalidomide

Introduction Overview

Generic Name

lenalidomide

Brand Name

Revlimid

Dosage Form

capsules (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg)

Drug Class

Miscellaneous antineoplastics, Other immunosuppressants

Pharmacokinetics

Absorption: Lenalidomide is rapidly absorbed following oral administration, with peak plasma concentrations generally observed within 0.5 to 4 hours. The absolute bioavailability of lenalidomide capsules is approximately 90%, indicating efficient systemic availability. Food intake may reduce the rate of absorption but does not significantly impact the extent of absorption, allowing for dosing with or without meals. Variability in absorption can be influenced by gastrointestinal function, and patients with GI disturbances may experience altered pharmacokinetics.

Distribution: Lenalidomide displays moderate volume of distribution, indicating distribution into both plasma and peripheral tissues. It exhibits low to moderate plasma protein binding (approximately 30%) predominantly to albumin, suggesting a significant free fraction available for pharmacologic activity. Distribution into the central nervous system is minimal due to the polarity and size of the molecule. Lenalidomide crosses the placenta, necessitating strict precautions in pregnancy.

Metabolism: Lenalidomide undergoes minimal hepatic metabolism. The majority of the drug is excreted unchanged in the urine, implying negligible involvement of hepatic cytochrome P450 enzymes in metabolism. There is limited evidence of metabolic transformation, primarily via hydrolysis pathways. This minimal metabolism reduces the likelihood of metabolic drug-drug interactions.

Elimination: Renal excretion is the primary route of elimination for lenalidomide, with approximately 80% of the drug recovered unchanged in urine within 24 hours. The elimination half-life ranges from 3 to 5 hours depending on the patient's population (healthy individuals vs. patients with multiple myeloma or MDS). Renal function has a significant impact on clearance; patients with impaired renal function exhibit reduced clearance and prolonged half-life, necessitating dose adjustments. Hemodialysis removes lenalidomide effectively, further influencing dosing regimens in dialysis-dependent patients.

Dosage Forms

Available Dosage Forms: Revlimid is supplied exclusively as oral capsules in the following dosage strengths: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The capsules contain lenalidomide powder and are formulated with inactive ingredients such as lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. Depending on the dose, capsule shells contain varying colors and components like gelatin, FD&C blue #2, yellow iron oxide, titanium dioxide, and black ink for product differentiation.

Dosages for Adults and Adolescents:
- Multiple Myeloma (in combination with dexamethasone): 25 mg orally once daily on Days 1 to 21 of repeated 28-day cycles until disease progression or unacceptable toxicity.
- Multiple Myeloma maintenance therapy post-autologous hematopoietic stem cell transplantation (auto-HSCT): 10 mg orally daily continuously on Days 1 to 28 for 3 cycles, then increased to 15 mg daily if tolerated, continued until disease progression or unacceptable toxicity.
- Myelodysplastic Syndrome (MDS) with transfusion-dependent anemia due to deletion 5q: 10 mg orally once daily continuously until disease progression or unacceptable toxicity.
- Follicular Lymphoma and Marginal Zone Lymphoma (previously treated): 20 mg orally once daily on Days 1 through 21 of repeated 28-day cycles for up to 12 cycles in combination with a rituximab product.
- Mantle Cell Lymphoma (relapsed or progressed): 25 mg orally once daily on Days 1 to 21 of repeated 28-day cycles until disease progression or unacceptable toxicity.

Specific Patient Populations: Dose modifications may be necessary for patients with renal impairment, reflecting reduced clearance and increased toxicity risk. Patients on dialysis require individualized dosing schedules. Adults with hepatic impairment generally do not necessitate dose adjustment due to minimal metabolism. Treatment duration is guided by clinical response, toxicity, and hematologic recovery, particularly in post-transplant maintenance therapy. Pediatric use has not been established. Elderly patients must be carefully monitored due to risk of cytopenias and thromboembolic events.

Mechanism Of Action

Lenalidomide, the active substance in Revlimid, functions primarily by binding to the intracellular protein cereblon (CRBN), a substrate receptor of the cullin ring E3 ubiquitin ligase complex. This binding alters the substrate specificity of the complex, targeting specific transcription factors such as IKZF1 and IKZF3 for ubiquitination and subsequent proteasomal degradation. The degradation of these transcription factors disrupts the survival and proliferation pathways of malignant cells, particularly in hematologic cancers such as multiple myeloma.

Beyond direct antiproliferative action, lenalidomide modulates the immune system. It enhances T-cell and natural killer (NK) cell-mediated cytotoxicity by increasing interleukin-2 (IL-2) and interferon-gamma production and stimulating the activity of cytotoxic lymphocytes against tumor cells. This immune activating effect contributes to tumor clearance in combination with its anti-proliferative activities.

Additionally, lenalidomide exhibits anti-angiogenic properties by inhibiting the secretion of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), limiting neovascularization that tumors require for growth and survival. This multi-pronged mechanism slows tumor progression.

Clinical studies reinforce that lenalidomide's mechanism integrates direct tumoricidal effects and host immune system modulation, resulting in improved outcomes when combined with other agents such as dexamethasone or rituximab. This differentiates lenalidomide from classic chemotherapy, positioning it as an immunomodulatory drug with multifaceted therapeutic benefits.

Pharmacological Actions

Immunomodulatory activity enhancing T-cell and NK cell function.
Antiproliferative effect through induction of targeted protein degradation (IKZF1/3) via cereblon binding.
Anti-angiogenic activity by downregulating VEGF and bFGF secretion.
Induction of apoptosis in malignant hematologic cells.
Modulation of cytokine production resulting in enhanced immune response.
Inhibition of tumor cell adhesion to bone marrow stroma.
Suppression of pro-inflammatory cytokines involved in tumor microenvironment.
Improved hematopoiesis in myelodysplastic syndromes with 5q deletion.
Synergistic effect with corticosteroids and monoclonal antibodies for cancer treatment.
Minimal hepatic metabolism reducing drug-drug interaction potential.
Direct inhibition of growth and survival pathways in lymphoma and myeloma cells.

Therapeutic Or Clinical Uses

Treatment of multiple myeloma in combination with dexamethasone.
Maintenance therapy for multiple myeloma following autologous hematopoietic stem cell transplantation.
Management of transfusion-dependent anemia in low- or intermediate-1-risk myelodysplastic syndromes with deletion 5q cytogenetic abnormality.
Treatment of relapsed or refractory mantle cell lymphoma after prior therapies including bortezomib.
Combination therapy with rituximab for previously treated follicular lymphoma.
Combination therapy with rituximab for previously treated marginal zone lymphoma.
Off-label use in certain lymphoproliferative disorders under clinical investigation.
Supportive therapy to prevent tumor progression and promote hematologic recovery.
If used cautiously within clinical trials, investigation in chronic lymphocytic leukemia.
Potential use in combination regimens enhancing immunotherapy efficacy in hematologic cancers.

Side Or Adverse Effects

Common upper respiratory tract symptoms including nasal congestion, sneezing, and sore throat.
Fatigue, somnolence, and general weakness.
Headache and tremors.
Musculoskeletal complaints such as muscle cramps and joint pain.
Nosebleeds and bleeding tendencies due to thrombocytopenia.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, constipation, and abdominal pain.
Skin reactions like rash, itching, and swelling.
Hematologic toxicities including neutropenia, anemia, and thrombocytopenia.
Increased risk of thromboembolic events such as deep vein thrombosis, pulmonary embolism, and stroke.
Serious allergic reactions including anaphylaxis and severe cutaneous adverse reactions.
Liver dysfunction manifesting as jaundice, elevated hepatic enzymes, and hepatotoxicity.
Symptoms indicative of tumor lysis syndrome: muscle weakness, numbness, confusion.
Infection susceptibility due to immunosuppression and leukopenia.
Rare development of secondary malignancies such as acute myeloid leukemia or lymphoma.
Potential teratogenicity causing severe birth defects and embryofetal death.

Precautions

Strict avoidance of use during pregnancy due to high teratogenic risk; women of childbearing potential must use two forms of contraception.
Men must use condoms during treatment and for 4 weeks after last dose to prevent pregnancy exposure.
Regular monitoring of blood counts to detect cytopenias early and adjust dose accordingly.
Assessment and management of thromboembolic risk including prophylactic anticoagulation when indicated.
Renal function evaluation prior to and during therapy to adjust dosing.
Avoid donating blood or sperm during treatment and for at least 4 weeks after discontinuation.
Use caution in patients with a history of blood clots, stroke, liver disease, or cardiovascular risk factors.
Careful handling of capsules to prevent direct contact with the powder; wash skin immediately if exposed.
Frequent pregnancy testing during therapy in women of childbearing potential.
Potential exacerbation of hypothyroidism; monitor thyroid function as indicated.
Inform patients about signs of infection, bleeding, and thromboembolic events requiring immediate medical attention.
Avoid concomitant use of hormonal contraceptives due to possible decreased efficacy.
Consider dose modification or interruption in case of severe adverse reactions or hematologic toxicity.
Advise patients on drug’s potential effects on fertility and counsel accordingly.
Avoid live vaccines during therapy due to immunosuppressive effects.

Warnings

Revlimid is contraindicated in pregnancy due to risk of severe, life-threatening birth defects or fetal death.
May cause serious blood clots including stroke, myocardial infarction, and pulmonary embolism.
Can cause severe myelosuppression resulting in low blood counts and increased infection or bleeding risk.
Potential for severe allergic reactions and severe skin reactions requiring immediate treatment discontinuation.
Risk of secondary malignancies such as leukemia or lymphoma may increase with prolonged use.
High risk of embryofetal toxicity necessitates enrollment in the Lenalidomide REMS program.
Renal impairment may lead to increased drug exposure and toxicity; dose adjustment required.
May impair fertility in both men and women.
Patients should not donate blood or sperm during treatment and for at least 4 weeks after last dose.
Avoid sharing medication with others due to risk of serious adverse effects.
Frequent blood monitoring is necessary to detect toxicity early.
Use cautiously in patients with pre-existing hepatic impairment.
Risk of tumor lysis syndrome, particularly in patients with high tumor burden.
Abrupt discontinuation without medical consultation is not advised due to risk of disease progression or adverse events.
Handling precautions must be strictly observed to prevent unintentional exposure.

Contraindication

Known hypersensitivity to lenalidomide or any component of the formulation.
Pregnancy due to high risk of severe fetal malformations and embryofetal death.
Severe hypersensitivity to thalidomide due to shared structural class and cross-reactivity potential.
Use in patients not enrolled in a certified Lenalidomide REMS program.
Patients with histories of severe clotting disorders where anticoagulation is contraindicated and cannot be managed.
Concomitant use with drugs contraindicated in immunosuppressed patients increasing infection risk.
Individuals unable or unwilling to comply with pregnancy prevention procedures.
Patients with severe uncontrolled infection or active severe liver disease.
Known lactose intolerance or allergy to any inactive ingredient components present in capsules.
Concurrent administration with strong inhibitors or inducers that are expected to significantly alter pharmacokinetics may be contraindicated without close monitoring.

Drug Interactions

Increased risk of bleeding may occur when taken with anticoagulants such as warfarin, heparin, or direct oral anticoagulants.
Concomitant use with corticosteroids (e.g., dexamethasone) can increase the risk of thromboembolism and immunosuppression.
Potential reduction in efficacy of hormonal contraceptives; alternative or additional contraceptive measures recommended.
Interaction with pembrolizumab (Keytruda) may potentiate immune-related adverse effects; close monitoring recommended.
Use with other immunosuppressants may increase susceptibility to infections and hematologic toxicity.
Co-administration with drugs excreted by renal pathways may require monitoring due to competition for elimination.
Limited potential for cytochrome P450-mediated interactions due to minimal hepatic metabolism.
Drugs that affect renal function (e.g., NSAIDs, diuretics) may alter lenalidomide clearance and toxicity profile.
Avoid concomitant use with live vaccines owing to immunosuppressive effects.
Non-steroidal anti-inflammatory drugs (NSAIDs) may elevate the risk of bleeding when taken concurrently.
Monitoring recommended when co-administered with strong CYP inhibitors or inducers for potential indirect effects.
Potential interaction with drugs that influence coagulation pathways or platelet function.
Herbal supplements affecting immune modulation or blood coagulation may lead to enhanced toxicity or reduced efficacy.
Concomitant administration with rituximab enhances therapeutic effect but may also increase risk of immunosuppression.
Careful assessment warranted when combined with other antineoplastic agents due to cumulative myelosuppressive effects.

Preparations Of The Drug

Oral capsules containing lenalidomide at strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.
Capsule shells contain inactive ingredients such as gelatin, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, magnesium stearate.
Imprinted capsule shells differ in color and markings according to dose for identification (e.g., blue, yellow iron oxide, black ink).
Available as commercially manufactured capsules packaged in blister packs or bottles, dispensed with REMS program restrictions.
All capsules are intended to be swallowed whole; powders should not be handled directly or opened due to toxicity risk.
Limited supply dispensed for a maximum 28-day period to comply with safety protocols.
Storage at controlled room temperature between 20°C to 25°C (68°F to 77°F) to preserve stability.
Packaging includes comprehensive instructions for handling, disposal, and risk mitigation to prevent environmental exposure.
Accompanied by educational materials and safety information mandated by the Lenalidomide REMS program.
Not formulated for intravenous or parenteral administration; strictly oral use only.
No generic formulations authorized outside restricted distribution programs due to safety concerns.
Dispensed with tamper-evident packaging to ensure integrity and authenticity.
Supplied by Bristol-Myers Squibb Company under trademarked brand name REVLIMID®.
Capsule formulations are designed for consistent dissolution and bioavailability over the dosing range.
Packaging and labeling conforms to regulatory requirements including pregnancy warnings and restricted use notices.